Dr. John Cush RheumNow
6 years 5 months ago
WHO scientific brief on NSAID use with COVID-19 - notes no direct evidence of harm in COVID-19, SARS, or MERS is available. Indirectly studies show no evidence of severe AE, health utilization, survival, or QOL with COVID-19 owing to NSAID https://t.co/KCOyvfPRxk
Dr. Alvin Wells gives a primer on Telerheumatology and Telemedicine in the era of COVID-19. This 1 hour Grand Rounds Presentation includes a 30 minute lecture, followed by stimulating 30 minutes of Q&A with a rheumatology attendee audience.
Dr. John Cush RheumNow
6 years 5 months ago
Great lecture Alvin! Moving Forward with Telemedicine - Watch it on RheumNow or here https://t.co/pOwRCboSYe https://t.co/yU585fsDp0
Dr. John Cush RheumNow
6 years 5 months ago
MGMA survey of practices finds that 48% of practices have experienced furloughs and 22% layoffs. There has been a 55% decrease in revenue and a 60% decrease in patient volume since the beginning of the pandemic https://t.co/20AUe9Qlro
Moving Forward with Telemedicine with Dr. Alvin Wells
Dr. Alvin Wells gives a primer on Telerheumatology and Telemedicine
Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness. These conclusions are based on elevated levels of ferritin and other inflammatory markers, drawing comparisons to rare diseases of uncontrolled systemic inflammation such as hemophagocytic lymphohistiocytosis (HLH), and macrophage activation syndrome (MAS).
Dr. John Cush RheumNow
6 years 5 months ago
Study from the National Inpatient Database shows that #RA pts have increased risk of hospitalizations for acute myocardial infarction. But compared to nonRA STEMI+ MI, RA- MI had a lower in-hospital mortality and cardiac arrests. https://t.co/lFHkqSgXbp
Dr. John Cush RheumNow
6 years 5 months ago
An immunogenicity study w/ live ZOSTAVAX given ~2-wks before tofacitinib showed after mean 27 mos - 5 of 100 TOFA rx pts developed H. Zoster (at 218, 280, 748, 741, 544 days post-vaccination). OOOPs; not very protective. Use Shingrix! https://t.co/hEIJTCjJ3t
Dr. John Cush RheumNow
6 years 5 months ago
GI experts COVID guidelines, state “Despite the potential for increased exposure to SARS-CoV-2, the limited available data and expert opinion suggest that patients with IBD do not appear to have a baseline increased risk of COVID-19infection" https://t.co/kGfIMJoZGI
Dr. John Cush RheumNow
6 years 5 months ago
Last weeks TNR Grand Rounds on "Evaluating the Febrile Rheumatic Patient" is now available as a podcast for listening on iTunes or SoundCloud Part 1 https://t.co/R5OGoB42Zi and Part 2 https://t.co/CP3HOd982A
Dr. John Cush RheumNow
6 years 5 months ago
Riociguat a guanylate cyclase stimulator w/ antiprolif & anti-inflamm effects studied in a DBRPCT in diffuse Systemic sclerosis; There was more improvement in mRSS (-2.09 vs -0.77), Raynauds (41% vs 26%) & FVC (2.7 vs 7.6) - but these were not significant https://t.co/7aEzdDxpVY
Patients with rheumatoid arthritis (RA) treated with abatacept (Orencia) had a lower risk of developing diabetes mellitus compared with those receiving certain tumor necrosis factor (TNF) inhibitors, a large cohort study suggested.
Journal of Experimental Medicine has published a paper from a consortium of researchers at Cold Spring Harbor Laboratory, the Feinstein Institutes for Medical Research, and the Research Institute of the McGill University Health Centre (RI-MUHC) on the potential of neutrophil extracellular traps (NETs) as the cause of the more severe manifiestations of COVID-19 infections.
Dr. John Cush RheumNow
6 years 5 months ago
NYU & Montreal Heart Instit. teaming on the COLCORONA study of Colchicine in early phase COVID-19 infx. TBD in 6,000 patients with mild forms of the disease. Dr. M Pillinger says colchicine, early on, may inhibit damaging inflammatory responses https://t.co/UTW2g6QU2r

